Cangene's HepaGam B(TM) Added to Novation's Product Listing Allowing the Product to Reach Nearly 2,500 Healthcare Organizations



    Listed TSX, Symbol:  CNJ

    TORONTO and WINNIPEG, March 13 /CNW/ - Cangene today announces that its
U.S. distributor for HepaGam B(TM), Apotex Corp., has signed a five-year
agreement with Novation, LLC for distribution of Cangene's hepatitis B
hyperimmune under the NOVAPLUS(R) private-label program. Novation is a leading
healthcare contract-services company and supplies nearly 2,500 healthcare
organizations in the United States. As the only hepatitis B hyperimmune in
Novation's product line-up, inclusion of HepaGam B(TM) in the NOVAPLUS(R)
program gives the drug considerable market presence and represents a
significant market opportunity.
    "We are extremely pleased that Apotex Corp. was able to secure this
arrangement, as reaching the number of customers represented by Novation would
be an extensive process," said Dr. John Langstaff, Cangene's president and
CEO.

    About HepaGam B(TM)
    HepaGam B(TM) is Cangene's hepatitis B immune globulin (human) injection,
which is a purified antibody or hyperimmune that is specific for the
hepatitis B virus. HepaGam B(TM) has been approved in the United States for
treatment of acute exposure to blood containing hepatitis B surface antigen
(HbsAg), perinatal exposure of infants born to HbsAg-positive mothers, sexual
exposure to HbsAg-positive persons and household exposure to persons with
acute HBV infection. Cangene manufactures HepaGam B(TM) in its Winnipeg
facility using a process similar to that of WinRho(R) SDF and Vaccinia immune
globulin, the Company's other FDA-approved drugs. Hepatitis B is a major
disease worldwide and a significant public health problem. A vaccine for
hepatitis B is available, yet the virus continues to cause significant disease
worldwide and pose a significant public health problem. Hyperimmune products
can be used in situations where a vaccine is not applicable. Approximately
60,000 new infections are seen annually. There are an estimated 1.25 million
chronically infected Americans, 20-30% of whom were infected as children.
Severe liver disease is seen in 15-25% of chronically infected people.

    About Cangene
    Cangene is one of Canada's largest and earliest biopharmaceutical
companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba.
Cangene carries out research and development in Mississauga, Ontario and in
Winnipeg. It uses patented manufacturing processes to produce plasma-derived
and recombinant therapeutic proteins. Cangene has three FDA-approved products
and a fourth that has been approved in Canada, one of its recombinant protein
products has received an approvable letter from the FDA and another has been
submitted for regulatory review in Canada, and in addition, the Company has
several more products in development at various stages. Capitalizing on its
drug manufacturing expertise, Cangene also operates a significant contract
research and manufacturing business using its Winnipeg facilities and the
resources of Baltimore, Maryland-based Chesapeake Biological Laboratories,
Inc. (a wholly owned subsidiary). An expansion in 2006 at the Winnipeg
location will increase the Company's capacity to fractionate plasma to
accommodate the growing manufacturing requirements. Cangene's website,
www.cangene.com, includes product and investor information, including past
news releases. Chesapeake's website is www.cblinc.com.

    About Novation
    Novation, LLC resulted from the consolidation of two national healthcare
alliances, VHA Inc. and the University HealthSystem Consortium. Through this
affiliation, it serves the purchasing needs of nearly 2,500 healthcare
operations, represents US$25 billion in annual purchases across all its
product offerings and manages contracts with more than 500 suppliers. It
serves healthcare operations of all sizes ranging from the largest healthcare
facilities to small, rural hospitals.

    Forward-looking information
    The reader should be aware that Cangene's businesses are subject to risks
and uncertainties that cannot be predicted or quantified; consequently, actual
results may differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or contribute to
such risks or uncertainties include, but are not limited to: the regulatory
environment including the difficulty of predicting regulatory outcomes;
changes in the value of the Canadian dollar; the Company's reliance on a small
number of customers including government organizations; the demand for new
products and the impact of competitive products, service and pricing; cost of
raw materials, especially the cost and antibody concentration in plasma;
fluctuations in operating results; government policies or actions; progress
and cost of clinical trials; reliance on key strategic relationships; costs
and possible development delays resulting from use of legal, regulatory or
legislative strategies by the Company's competitors; uncertainty related to
intellectual property protection and potential cost associated with its
defence; the Company's exposure to lawsuits, and uncertainties related to
estimates and judgments used in preparation of financial statements in
accordance with GAAP and related standards, and other matters beyond control
of management.
    Risks and uncertainties are discussed more extensively in the MD&A
section of the Company's most recent annual report and annual information
form, which are available on the Company's website or on SEDAR at
www.sedar.com. Scientific information that relates to unapproved products or
unapproved uses of products is preliminary and investigative. No conclusions
can or should be drawn regarding the safety or efficacy of such products. Only
regulatory authorities can determine whether products are safe and effective
for the uses being investigated. Healthcare professionals are directed to
refer to approved labelling for products and not rely on information presented
in news releases.
    The cautionary statements referred to above should be considered in
connection with all written or oral statements, especially forward-looking
statements, that are made by the Company or by persons acting on its behalf
and in conjunction with its periodic filings with Securities Commissions,
including those contained in the Company's news releases and most recently
filed annual information form. Forward-looking statements can be identified by
the use of words such as "expects", "plans", "will", "believes", "estimates",
"intends", "may", "bodes" and other words of similar meaning (including
negative and grammatical variations). Should known or unknown risks or
uncertainties materialize, or should management's assumptions prove
inaccurate, actual results could vary materially from those anticipated. The
Company undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable law.

    %SEDAR: 00002351E




For further information:

For further information: Jean Compton, Manager, Investor Relations, at
(905) 405-2900, or by email at jcompton@cangene.com

Organization Profile

Cangene Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890